(HealthDay News) — For men with distant, de novo, metastatic prostate cancer (PCa), Asian ethnicity is associated with superior median overall survival (OS) and PCa-specific mortality (PCSM), according to a study published online in Cancer.
Brandon Bernard, MD, from the Dana-Farber Cancer Institute in Boston, and colleagues identified men with distant, de novo, metastatic PCa from 2004 to 2012 from the Surveillance, Epidemiology, and End Results (SEER) registry. For each race the authors determined patterns of presentation, OS, and PCSM. To assess outcomes of androgen-deprivation therapy (ADT) and ADT plus docetaxel for each race they retrospectively reviewed E3805 clinical trial data.
The researchers found that of all PCa diagnoses, distant, de novo, metastatic disease was diagnosed in 4.2%, 5.8%, 5.7%, 5.5%, and 8.8% of non-Hispanic whites, Hispanic whites, blacks, Asians/Pacific Islanders, and American Indians/Alaska Natives, respectively, in SEER. Median OS differed by race, with Asian men having superior OS compared to men of other races (30 vs 24 to 25 months; P < 0.001). Compared with other races, Asian men also had superior median PCSM (54 vs 35 to 40 months; P < 0.001). Chemohormonal therapy in E3805 correlated with a median OS of 58.1 and 57.6 months in non-Hispanic whites and blacks, respectively; there were few Asian participants in E3805.
“Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race,” the authors write.
- Bernard B, Muralidhar V, Chen YH, et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 5 January 2017. doi: 10.1002/cncr.30503. [Epub ahead of print]